Shinpoong Pharmaceutical Co.,Ltd (019175.KS)
KSE · KRW · Healthcare · Drug Manufacturers - Specialty & Generic
₩13,130 (+1.47%) as of
Key statistics
- Market cap
- 678.93B
- Dividend yield
- 0.00%
- 52-week range
- 7,570.00 – 28,500.00
- Beta
- 1.14
- Revenue (TTM)
- 239.07B
- Profit margin
- -0.34%
- Volume
- 131.00
About Shinpoong Pharmaceutical Co.,Ltd
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; and drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; prescription drugs; wound dressings; health functional food; and over the counter products. In addition, the company engages in business management and exports its products to approximately 50 countries. The company was founded in 1962 and is headquartered in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Seoul, South Korea
- Employees
- 656
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.